<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204694</url>
  </required_header>
  <id_info>
    <org_study_id>7350</org_study_id>
    <nct_id>NCT04204694</nct_id>
  </id_info>
  <brief_title>Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock</brief_title>
  <acronym>INTERSEP</acronym>
  <official_title>Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is the most severe form of a bacterial infection, affecting 24 million patients&#xD;
      per year worldwide, with a high mortality (&gt; 30%).&#xD;
&#xD;
      Septic shock is defined by an acute circulatory failure, with low blood pressure and&#xD;
      insufficient oxygen supply to organs. This circulatory failure is related to vascular&#xD;
      damages, in which the endothelial vascular tissue is impaired by inflammatory mechanisms,&#xD;
      with release of circulating endothelial cells in the blood.&#xD;
&#xD;
      Therefore, modulating inflammation on the vascular endothelial tissue could be a therapeutic&#xD;
      strategy, and the investigators focus on the role of the type I interferons on the&#xD;
      endothelial tissue because of the demonstrated role of type I interferons during septic&#xD;
      shock.&#xD;
&#xD;
      Thus the investigators proceed to an observational study, in which the primary purpose will&#xD;
      be to show a higher expression of type I interferon receptors on circulating endothelial&#xD;
      cells in patients with septic shock compared to control subjects.&#xD;
&#xD;
      Concerning secondary purposes, the investigators will record mortality at d3, d7 and d28,&#xD;
      perform assays about types I, II and III interferons in plasma, and test anti-interferon on&#xD;
      endothelial cells ex vivo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of the activated interferon-α receptors (IFNAR) by circulant endothelial cells</measure>
    <time_frame>Within 12 hours following the onset of norepinephrin for septic shock (day 1)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Patient in septic shock</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>blood donor tests</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3-time blood sampling for septic shock patients</intervention_name>
    <description>15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock</description>
    <arm_group_label>Patient in septic shock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Only one blood sampling for controls patients</intervention_name>
    <description>15 mL blood are sampled from a blood donation</description>
    <arm_group_label>blood donor tests</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will have two groups :&#xD;
&#xD;
          1. Patients with septic shock hospitalized in the ICU from Strasbourg University Hospital&#xD;
&#xD;
          2. Controls: blood donors recruited by the French blood establishment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  For all subjects&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  For females: negative pregnancy test&#xD;
&#xD;
          -  Subject covered by health insurance&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Patients with septic shock&#xD;
&#xD;
          -  Patients must be in ICU&#xD;
&#xD;
          -  Septic shock defined by the Sepsis-3 criteria [1]&#xD;
&#xD;
          -  Inclusion within the 12 hours following the onset of norepinephrin&#xD;
&#xD;
          -  Controls :&#xD;
&#xD;
          -  Blood donors&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Moribund&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Absence of written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de réanimation médicale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

